X0306 4 2017-01-31 0 0001370053 ANAPTYSBIO INC ANAB 0001388325 Novo A/S TUBORG HAVNEVEJ 19 HELLERUP G7 2900 DENMARK 0 0 1 0 Common Stock 2017-01-31 4 C 0 1428571 A 1428571 D Common Stock 2017-01-31 4 C 0 486820 A 1915391 D Common Stock 2017-01-31 4 C 0 312986 A 2228377 D Common Stock 2017-01-31 4 C 0 673454 A 2901831 D Common Stock 2017-01-31 4 X 0 81673 A 2983504 D Common Stock 2017-01-31 4 P 0 50000 15.00 A 3033504 D Series B Preferred Stock 2017-01-31 4 C 0 1428571 0.00 D Common Stock 1428571 0 D Series C Preferred Stock 2017-01-31 4 C 0 486820 0.00 D Common Stock 486820 0 D Series C-1 Preferred Stock 2017-01-31 4 C 0 312986 0.00 D Common Stock 312986 0 D Series D Preferred Stock 2017-01-31 4 C 0 673454 0.00 D Common Stock 673454 0 D Series C Preferred Stock Warrant (Right to Buy) 4.55 2017-01-31 4 X 0 117235 0.00 D 2018-11-04 Common Stock 117235 0 D The Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock (the "Preferred Stock") had no expiration date and was convertible at any time at the holder's election. Immediately prior to the closing of the Issuer's initial public offering (the "IPO Closing"), the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock. Immediately prior to the IPO Closing, the warrant became exercisable for shares of common stock. The shares acquired upon exercise of the warrant were acquired through a net exercise procedure in accordance with the terms of the warrant and did not involve any sale of shares. All shares received upon such exercise are subject to a lock-up agreement between the Reporting Person and the underwriters. Represents a purchase from the underwriters in the Issuer's initial public offering. Novo A/S is a Danish limited liability company. The board of directors of Novo A/S (the "Novo Board"), currently comprised of Sten Scheibye, Goran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared investment and voting control over the securities of the Issuer held by Novo A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares. /s/ Peter Haahr, Chief Financial Officer of Novo A/S 2017-01-31